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Abstract
Background: Endocervical adenocarcinomas (ECAs) and endometrial adenocarcinomas (EMAs)
are malignancies that affect uterus; however, their biological behaviors are quite different. This
distinction has clinical significance, because the appropriate therapy may depend on the site of
tumor origin. The purpose of this study is to evaluate 3 different scoring mechanisms of p16INK4a
immunohistochemical (IHC) staining in distinguishing between primary ECAs and EMAs.
Methods: A tissue microarray (TMA) was constructed using formalin-fixed, paraffin-embedded
tissue from hysterectomy specimens, including 14 ECAs and 24 EMAs. Tissue array sections were
immunostained with a commercially available antibody of p16INK4a. Avidin-biotin complex (ABC)
method was used for antigens visualization. The staining intensity and area extent of the IHC
reactions was evaluated using the semi-quantitative scoring system. The 3 scoring methods were
defined on the bases of the following: (1) independent cytoplasmic staining alone (Method C), (2)
independent nucleic staining alone (Method N), and (3) mean of the sum of cytoplasmic score plus
nucleic score (Method Mean of C plus N).
Results: Of the 3 scoring mechanisms for p16INK4a expression, Method N and Method Mean of C
plus N showed significant (p-values < 0.05), but Method C showed non-significant (p = 0.245)
frequency differences between ECAs and EMAs. In addition, Method Mean of C plus N had the
highest overall accuracy rate (81.6%) for diagnostic distinction among these 3 scoring methods.
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and Method Mean of C plus N can significantly signal to distinguish between ECAs and EMAs; while
Method C cannot do. Method Mean of C plus N is the most promising and favorable means among
the three scoring mechanisms.
Background
The histomorphologic overlap of ECA and EMA can make
differentiation difficult on H&E in small pre-operative
biopsy or curetting specimens. Ascertaining the site of
cancer origin may be difficult, but plays an important role
in guiding treatment. For the EMA, staging is surgical;
however, for the primary ECA, staging is clinical. Treat-
ment protocols may differ substantially between both of
them. [1-3]
Previous studies have shown that certain immunohisto-
chemical markers may be helpful in distinguishing
between ECAs and EMAs. A traditional 3-marker panel
(ER/Vim/CEA) has previously been proposed to make the
distinction. A positive ER, Vim and a negative CEA result
indicates an EMA; a negative ER, Vim and positive CEA
result indicates an ECA. There are, however, many unex-
pected aberrant immunoexpressions not characteristic of
either primary ECAs or EMAs. No study has identified one
marker that clearly and consistently makes this distinction
in all cases. [4-8]
Recent study has focused on other markers, such as
p16INK4a, which may express in different intensities, stain-
ing patterns and subcellular localizations in various
malignancies and tissues. It is also reported that ECAs
tends to be positively and diffusely expressed by p16INK4a,
whereas EMAs tends to be negatively or focally expressed
by p16INK4a in routine whole-sectioned tissue slides. [9-
13] To date, there is not yet consensus to define the opti-
mal scoring methods of p16INK4a immunoexpression in
various tissue samples, especially in those small sizes of
pre-operative biopsy or curetting specimens of endocervix
or endometrium. In this study, our objective was to pro-
pose the appropriately scoring methods and to report that
these methods can be easily applied to p16INK4a immuno-
histochemistry (IHC) as a diagnostic adjunct in distin-
guishing between ECAs and EMAs. [14-18]
Materials and methods
Study materials
The study material consisted of slides and selected forma-
lin-fixed, paraffin-embedded tissue blocks from 38 hyster-
ectomy specimens retrieved from the archives of the
Tissue Bank, Clinical Trial Center, Chung-Shan Medical
University Hospital. These specimens of known origin,
endocervix or endometrium, were accessioned between
2004 and 2008. The cases studied included EMAs (n =
24), as well as ECAs (n = 14). Two board-certified pathol-
ogists (CP Han and LF Kok) reviewed all H&E stained
slides for these cases. A slide with tumor representative
was selected and circled from each case. In the next step,
the area corresponding to the selected area on the slide
was also circled on the block with an oil marker pen. All
these donors' tissue blocks were sent to the Biochiefdom
International Co. LTD, Taiwan for tissue microarray con-
struction. They were cored with a 1.5 mm diameter needle
and transferred to a recipient paraffin block. The recipient
block was sectioned at 5 um, and transferred to silanized
glass slides.
Immunohistochemical staining
Using the Avidin-Biotin Complex (ABC) technique,
immunohistochemistry and antigen retrieval methods
were applied in the same manner as described in previous
literature.[17] Briefly, all the 1.5 mm and 5 um cores of
tissue array specimens embedded in paraffin slice on
coated slides, were washed in xylene to remove the paraf-
fin, rehydrated through serial dilutions of alcohol, fol-
lowed by washings with a solution of PBS (pH 7.2). All
subsequent washes were buffered via the same protocol.
Treated sections were then placed in a citrate buffer (pH
6.0) and heated in a microwave for two 5-minute sessions.
The samples were then incubated with a monoclonal anti-
mouse p16INK4a antibody (F12, sc-1661, Santa Cruz,
1:200 dilution) for 60 minutes at 25°C. The conventional
streptavidin peroxidase method (DAKO, LSAB Kit K675,
Copenhagen, Denmark) was performed for signal devel-
opment and the cells were counter-stained with hematox-
ylin. Negative controls were obtained by excluding the
primary antibody, and positive controls were simultane-
ously obtained by staining tissues of squamous cell carci-
noma of uterine cervix. This slide was mounted with gum
for examination and capture by the Olympus BX51 micro-
scopic/DP71 Digital Camera System for study compari-
son.
Scoring of IHC staining results
The core of specimens on the tissue microarray (TMA)
slides were examined and scored using a two-headed
microscope. Because p16INK4a IHC scoring algorithms
have not been optimized and standardized, we inter-
preted the cytoplasmic staining and nucleic staining sepa-
rately as well as mixed cytoplasmic/nucleic staining
collectively. We also adopted the German semi-quantita-
tive scoring system in considering the staining intensityPage 2 of 10
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in previous studies. [7-18]Every tumor was given a score
according to the intensity of the nucleic or cytoplasmic
staining (no staining = 0, weak staining = 1, moderate
staining = 2, strong staining = 3) and the extent of stained
cells (0% = 0, 1–10% = 1, 11–50% = 2, 51–80% = 3, 81–
100% = 4; negative means 0% area staining, focally posi-
tive means 1–80% area staining, diffusely positive means
81–100% area staining). The final immunoreactive score
was determined by multiplying the intensity scores with
the extent of positivity scores of stained cells, with the
minimum score of 0 and a maximum score of 12. [19-23]
Statistical analysis
The threshold for differentiating between final positive
and negative immunostaining was set at 4 for interpreta-
tion. This optimal cut-off value was determined by using
the receiver operating characteristic (ROC) curve analysis
(Metz, 1978; Zweig & Campbell, 1993) in this
study.[24,25] Score of 4 points or greater was considered
positive for p16INK4a expression. A negative stain was clas-
sified as having an immunostaining score of 0 to 3 (essen-
tially negative) and indicated a diagnosis of an EMA;
whereas a positive stain was classified as having an immu-
nostaining score of 4 to 12 (at least moderately positive in
at least 11–50% of cells) and indicated a diagnosis of an
ECA. A chi-squared or Fisher's exact test was performed to
test the frequency difference of p16INK4a immunostaining
(positive vs. negative) between groups of two primary
adenocarcinomas (ECAs vs EMAs). A nonparametric anal-
ysis of Mann-Whitney U-test was used to test the immu-
nostaining raw scores between the two adenocarcinomas,
given the fact that the analytical IHC scores were not nor-
mally distributed. In addition, we also examined associa-
tions among the 3 different scoring mechanisms, based
on the subcellular localizations of p16INK4a expression,
including (1) Method C, (2) Method N, and (3) Method
Mean of C plus N. The nonparametric Spearman's rho cor-
relation coefficient was used to analyze associations
between pairs of these three types of p16INK4a scores. Data
were analyzed using standard statistical software (SPSS,
Inc., Chicago, IL). All tests were 2-sided and the signifi-
cance level was 0.05.
To evaluate and compare the patterns of p16INK4a expres-
sion in making a diagnostic distinction of primary ECAs
from primary EMAs, the sensitivity, specificity, accuracy,
and the positive and negative predictive values (PPV and
NPV respectively) were compared and displayed. Sensitiv-
ity is defined as the probability of positive p16INK4a stain
in primary ECAs. Specificity is, on the other hand,
defined, as the probability of negative p16INK4a stain in
primary EMAs.18 Overall accuracy is the proportion of true
diagnosis of ECAs and EMAs in total number of p16INK4a
scoring tests. Positive predictive value is the probability
that a patient with a positive p16INK4a expression has a pri-
mary adenocarcinoma of endocervical origin. Negative
predictive value is the probability that a person with a
negative p16INK4a expression has a primary adenocarci-
noma of endometrial origin.[26] In order to assess
whether the test results were statistically different from
each other based on correct diagnosis, McNemar's test was
performed. A p-value < 0.05 was considered significant.
Results
For evaluation of p16INK4a immunohistochemistry,
nucleic and cytoplasmic stains were taken into account
separately as well as collectively for all cases. H&E (Figure
1a and Figure 2a) and immunoreactivities for p16INK4a can
be identified in representatives of ECAs (Figure 1b, 1c and
1d) and EMAs (Figure 2b, 2c and 2d). The p16INK4a expres-
sion in ECAs was observed both in nuclei and cytoplasms
with varying degrees of staining intensity and area extent.
Nucleic stains were predominant in 7 out of 14 cases (Fig-
ure 1b), cytoplasmic stains were predominant in 2 out of
14 cases (Figure 1c), while both nucleic and cytoplasmic
stains were co-dominant in 5 out of 14 cases (Figure 1d).
On the other hand, the p16INK4a expression in EMAs was
also observed both in nuclei and cytoplasms with varying
degrees of staining intensity and area extents, except for 4
out of 24 cases with a score of 0. Nucleic stains were pre-
dominant in 8 out of 24 cases (Figure 2b), cytoplasmic
stains were predominant in 6 out of 24 cases (Figure 2c),
while both nucleic and cytoplasmic stains were co-domi-
nant in 6 out of 24 cases (Figure 2d).
The IHC results of these three p16INK4a scoring mecha-
nisms, (1) Method C, (2) Method N, (3) Method Mean of
C plus N, are summarized in Table 1. By using score of 4
as a cut-off point, except for Method C, the other two scor-
ing mechanisms based on N, and Mean of C plus N,
showed significant frequency differences between immu-
nostaining (positive vs. negative) in tissues from the two
adenocarcinomas (ECA vs. EMA) in origin. Individually,
(1) Method C stained positive in 5 out of 14 (35.7%) ECA
tumors and 4 out of 24 (16.7%) stained positive in EMA
tumors (p = 0.245), with median staining score and range
of 2 (0–12) and 2 (0–12), respectively (p = 0.152); (2)
Method N stained positive in 11 out of 14 (78.6%) ECA
tumors and 7 out of 24 (29.2%) stained positive in EMA
tumors (p < 0.001), with median staining score and range
of 5 (2–12) and 2 (0–9), respectively (p < 0.001); (3)
Method Mean of C plus N stained positively in 10 out of
14 (71.4%) ECA tumors and 3 out of 24 (12.5%) stained
positively in EMA tumors (p < 0.001), with median stain-
ing score and range of 4.25 (2–12) and 2 (0–10.5), respec-
tively (p < 0.001). In summary, Method C did not show
statistically significant, whereas Method N and Method
Mean of C plus N revealed statistically significant fre-Page 3 of 10
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ECAs and EMAs.
The associations between these three scoring methods in
ECAs and EMAs were also explored and shown in Figure
3. The immunostaining scores based on Method C were
significantly positive correlated with those based on
Method N in EMAs (Figure 3 a1 and a2, Spearman's rho =
0.537, p = 0.007), but the correlation was non-significant
in ECAs (Figure 3 d1 and d2, Spearman's rho = -0.128, p
= 0.663). Method C scores also exhibited significant posi-
tive correlation with Method Mean of C plus N scores
(Figure 3 b1 and b2, Spearman's rho = 0.840, p < 0.001)
in EMAs but did not exhibit significant positive correla-
tion in ECAs (Figure 3 e1 and e2, Spearman's rho = 0.456,
p = 0.101). Moreover, Method N scores exhibited signifi-
cant positive correlation with Method Mean of C plus N
scores in both EMAs (Figure 3 c1 and c2, Spearman's rho
= 0.855, p < 0.001) and ECAs (Figure 3 f1 and f2, Spear-
man's rho = 0.713, p = 0.003).
Clinicians may also find interesting the following param-
eters when judging the test effectiveness of p16INK4a
expression as a marker for diagnostic distinction between
Immunohistochemical analysis of p16INK4a staining in endocervical adenocarcinomasFigure 1
Immunohistochemical analysis of p16INK4a staining in endocervical adenocarcinomas. (a) Photomicrograph 
revealed adenocarcinoma of endocervix, endocervical type, H&E stain. (b) Photomicrograph revealed tumor with more pre-
dominant p16INK4a staining at nuclei than that at cytoplasms. Focally moderately positive nucleic staining and no cytoplasmic 
staining were identified. (c) Photomicrograph revealed tumor with more predominant p16INK4a staining at cytoplasms than that 
at nuclei. Diffusely moderately positive cytoplasmic staining and focally weakly nucleic staining were identified. (d) Photomicro-
graph revealed tumor with dual prdominat p16INK4a staining at both cytoplasms and nuclei. Diffusely strongly positive nucleic 
staining and cytoplasmic staining were identified. All photomicrographs a, b, c, d were taken in median-powered, ×200Page 4 of 10
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ance of these three different scoring mechanisms for
measuring p16INK4a expression in distinguishing 14 ECAs
from 24 EMAs. (1) When using Method C, the sensitivity
of positively stained ECAs was 35.7% (5/14) and PPV was
55.6%, whereas the specificity of negatively stained EMAs
was 83.3% (20/24) and NPV was 69.0%. The overall accu-
racy rate was 65.8%. (2) When using Method N, the sen-
sitivity was 78.6% (11/14) and PPV was 61.1%, whereas
the specificity was 70.8% (17/24) and NPV was 85%. The
overall accuracy rate was 71.4%. (3) When using Method
Mean of C plus N, the sensitivity was 71.4% (10/14) and
PPV was 76.9%, whereas the specificity (21/24) was
87.5% and NPV was 84.0%. The overall accuracy rate was
81.6%, the highest among the three scoring methods
(table 2). Furthermore, the 95% confidence intervals
(CIs) of these performance parameters were calculated
and provided in Table 2 for these three scoring methods.
It was clearly that the 95% CI of the sensitivity value for
Method C did not overlap with Method N, and Method
Mean of C plus N as well. This implied that the perform-
ances of sensitivities were different among these three
scoring methods especially for Method C. To confirm this
finding, McNemar's test was further used to compare the
Immunohistochemical analysis of p16INK4a staining in endometrial adenocarcinomasFigure 2
Immunohistochemical analysis of p16INK4a staining in endometrial adenocarcinomas. (a) Photomicrograph 
revealed adenocarcinoma of endometrium, endometroid type, H&E stain. (b) Photomicrograph revealed tumor with more 
predominant p16INK4a staining at nuclei than that at cytoplasms. Diffusely moderately positive nucleic staining and no cytoplas-
mic staining were identified. (c) Photomicrograph revealed tumor with more predominant p16INK4a staining at cytoplasms than 
that at nuclei. Diffusely moderately positive cytoplasmic staining and focally weakly nucleic staining were identified. (d) Phot-
omicrograph revealed tumor with dual prdominat p16INK4a staining at both cytoplasms and nuclei. Diffusely strongly positive 
cytoplasmic staining and nucleic staining were identified. All photomicrographs a, b, c, d were taken in median-powered, ×200.Page 5 of 10
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methods. It demonstrated that the positive rates between
Method C and Method N were statistically significantly
different (p = 0.022), although non-significances were
seen in Method C vs. Method Mean of C plus N (p =
0.219) as well as Method N vs. Method Mean of C plus N
(p = 0.125).
Discussion
Distinguishing between ECAs and EMAs before planning
the patient treatment is clinically important. When the
tumor involves both the uterine endometrium and the
endocervix, it becomes difficult to distinguish the primary
site of the tumor during preoperative assessment of the
limited sizes of biopsy or curetting specimens. In this
Table 1: Scoring methods based on p16INK4a expression patterns and subcellular loci in ECA and EMA
Scoring Method Score categories ECA EMA p-value
C Score 0–3 9 (64.3%) 20 (83.3%) .245a
Score 4–12 5 (35.7%) 4 (16.7%)
Median (Range) 2 (0–12) 2 (0–12) .152
N Score 0–3 3 (21.4%) 17 (70.8%) .006a
Score 4–12 11 (78.6%) 7 (29.2%)
Median (Range) 5 (2–12) 2 (0–9) <0.001b
Mean of C plus N Score 0–3 4 (28.6%) 21 (87.5%) <0.001a
Score 4–12 10 (71.4%) 3 (12.5%)
Median (Range) 4.25 (2–12) 2 (0–10.5) <0.001b
PS:
1. C: Method of scoring based on independent cytoplasmic staining alone, irrespective of nucleic staining.
2. N: Method of scoring based on independent nucleic staining alone, irrespective cytoplasmic staining.
3. Mean of C plus N: Method of scoring based on mean of cytoplasmic score plus nucleic score.
Note:
• The "a" is Chi-squared test with continuity correction or Fisher exact test, the "b" is Mann-Whitney U test using exact significant.
•Using score 4 points as a cutoff, the immunostains are defined "negative" for scores from 0 to 3, and "positive" for scores from 4 to 12 points.
Scatter plots showing the Spearman's rho correlation coefficients (p value) for the associations between pairs of these three types of p16INK4a scoring mechanism in endoc rvical adeno arcinomas and endometrial de ocarcinomasFigure 3
Scatter plots showing the Spearman's rho correlation coefficients (p value) for the associations between pairs 
of these three types of p16INK4a scoring mechanisms in endocervical adenocarcinomas and endometrial adeno-
carcinomas. (1) a1/a2 and d1/d2: Method C was positively correlated with Method N in EMAs, but was not in ECAs. (2) 
b1/b2 and e1/e2: Method C was positively correlated with Method Mean of C plus N in EMAs but was not in ECAs. (3) c1/
c2 and f1/f2: Method N was positively correlated with Method Mean of C plus N in both EMAs and in ECAs.Page 6 of 10
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both ECAs and EMAs. We also investigate the most appro-
priate and effective p16INK4a IHC scoring methods in dis-
tinguishing these two types of gynecologic cancers in
Taiwanese women. Our valuable domestic data can be
extrapolated to women in general and will be helpful in
referring and managing such cases worldwide.
The p16INK4a (cyclin-dependent kinase inhibitor 4) is a
tumor suppressor protein that binds to cyclin-cdk4/6
complexes, which blocks kinase activity and inhibits pro-
gression to the S phase of the cell cycle in the
nucleus.[10,15,27-35] However, interpretation of IHC
data of p16INK4a staining results is complicated because of
its unclear biological significance of cytoplasmic staining
and lack of universal accepted algorithm in scoring meth-
odology. Cytoplasmic reactivity is often regarded as unex-
pected, unspecific event.[36] Some consider only nucleic
p16INK4a labeling in tumor cells to be positive and ignore
cytoplasmic staining.[16,32] Others state that both
nucleic and cytoplasmic immunoreactivities in tumor
cells are characteristic and are indeed due to p16INK4a
expression. [24-28] It has also been reported that strong
cytoplasmic staining in mammary carcinomas is associ-
ated with negative prognostic factors, such as low differen-
tiation, p53, Ki-67 labeling etc. We have learned that
despite nucleic expression, p53 tumor suppressor protein
is localized on cell cytoplasm, where it is regarded as a way
of functional inactivation. [29-31] From our data, we can-
not draw any conclusion yet about the biological signifi-
cance of cytoplasmic p16INK4a expression. The knowledge
about the functional meaning of cytoplasmic p16INK4a
expression is still limited and further large-scale studies
are encouraged in various human tissues and tumors.
There are a variety of IHC scoring methods including com-
puter-based plans in literatures, and still seems to be no
generally accepted protocols in research laboratories and
clinical practices for rating and scoring the immunostain-
ing results. Comparing commercially derived computer-
based programs with the conventional analyses by pathol-
ogists, there are still lacks of optimized and standardized
IHC scoring algorithms. As a result, the objective accuracy
did not significantly improve clinical outcome measures.
[33-36]
There are also various quantitative scoring mechanisms of
p16INK4a expression using various cut-off thresholds in lit-
erature. Without mentioning the grading of intensity,
Vallmanya Llena FR reports the cut-off point for p16INK4a
expression to be 15% positively staining extent.[37] Fre-
gonesi PA defines the cut-off point for p16INK4a expression
to be 5% cells stained positively. [32] Khoury T used the
positive staining area >50% as a cut-off.[16] They all took
both nucleic and cytoplasmic p16INK4a IHC staining into
considerations. However, Huang HY regarded any nucleic
labeling of p16INK4a to be positive, irrespective of cytoplas-
mic staining.[38] Kommoss S only used the nucleic stain-
ing patterns for p16INK4a evaluation.[39] Milde-Langosch
K defined the 12-tier scoring system which was also used
in this study.[40] In addition, we investigated the three
p16INK4a IHC scoring mechanisms and determined the
most effective means in the distinction between ECAs and
EMAs. These results can potentially be applied to future
clinically diagnostic techniques, when using
p16INK4aimmunohistochemistry.
McCluggage WG (2003) and Mittal K (2007) stated that a
diffuse, strong staining pattern of p16INK4a, involving
nearly all tumor cells tends to be an ECA, whereas, focal,
patchy staining pattern of p16INK4a involving 0–50% of
cells tends to be an EMA in routine whole-sectioned tissue
slides.[15,17] We did not use the patchy or diffuse pattern
of p16INK4a IHC staining as a diagnostically distinctive cri-
terion between ECAs and EMAs in this TMA study,
because we think that cases with primary EMA may seem
to over-express p16INK4a beyond the limited 1.5 mm core
area and therefore mimic a diffuse pattern of ECA pri-
mary. Instead, we preferred to use the semi-quantitative
scoring system in considering the 0–3 points of staining
intensity and 0–4 points of staining area extent by multi-
plying both, yielding a range of score 0 to 12 points. We
then divided the results by an appropriate cut-off thresh-
old of 4 to a two-tier of negative (0–3 points) or positive
(4–12 points) for interpretation. The mixed cytoplasmic
and nucleic stains with varying degrees of intensity and
Table 2: Diagnostic performance of 4 scoring methods for 
measuring p16INK4a expression in correctively distinguishing 14 
ECA from 24 EMA
Scoring method C N Mean of C plus N
Sensitivity 35.7% 78.6% 71.4%
(95% CI) (20.5%,50.9%) (65.5%,91.6%) (57.1%,85.8%)
Specificity 83.3% 70.8% 87.5%
(95% CI) (71.5%,95.2%) (56.4%,85.3%) (77.0%,98.0%)
PPV 55.6% 61.1% 76.9%
(95% CI) (39.8%,71.4%) (45.6%,76.6%) (63.5%,90.3%)
NPV 69.0% 85.0% 84.0%
(95% CI) (54.3%,83.7%) (73.6%,96.4%) (72.3%,95.7%)
Accuracy 65.8% 73.7% 81.6%
(95% CI) (50.7%,80.9%) (59.7%,87.7%) (69.3%,93.9%)
PS:
1. C: Method of scoring based on independent cytoplasmic staining 
alone, irrespective of nucleic staining.
2. N: Method of scoring based on independent nucleic staining alone, 
irrespective cytoplasmic staining.
3. Mean of C plus N: Method of scoring based on mean of cytoplasmic 
score plus nucleic score.
Note:
Negative p16INK4a expression (score 0–3) tends to be EMA, whereas 
positive p16INK4a expression (scores 4–12) tends to be ECA.Page 7 of 10
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These discrepancies of p16INK4a expression in different
subcellular compartments (cytoplasmic vs. nucleic) may
have caused significant difficulties in the scoring process.
In this study, we defined 3 scoring mechanisms of the
p16INK4a IHC expressions, as follows: (1) independent
cytoplasmic staining alone, irrespective of nucleic staining
(Method C), (2) independent nucleic staining alone, irre-
spective of cytoplasmic staining (Method N), and (3)
mixed cytoplasmic with nucleic expression, using mean of
the sum of cytoplasmic score plus nucleic score (Method
Mean of C plus N). Of the 14 ECA and 24 EMA tissue sam-
ples in this study, we found that only 2 (Method N as well
as Method Mean of C plus N) out of the total 3 scoring
methods showed significant frequency differences (p <
0.05), whereas the third scoring method (Method C) did
not show a significant difference (p > 0.05) in distinguish-
ing between ECAs and EMAs. (Table 1) We can not com-
pletely yet rule out the possibility of the indigenous
heterogeneity within individual tumors, leading to differ-
ent p16INK4a expression patterns in various areas within
the same tissue samples, because of the limited number of
cases (14 ECA and 24 EMA tissues) and limited core size
(1.5 mm) of the tumor specimens in TMA. However, our
data showed that cytoplasmic p16INK4a expression corre-
lated significantly with nucleic p16INK4a expression (p =
0.007) in EMAs, but not to do so (p = 0.663) in ECA. In
short, cytoplasmic and nucleic staining correlates closely
in EMAs, but do not in ECAs.
For the p16INK4a-marker characteristics and test effective-
ness of ECA and EMA discrimination, the goal is to mini-
mize the chance or probability of false positive and false
negative results, and to maximize the probability of true
positive and true negative results. According to our data,
one method based on C (Method C) does not show signif-
icant frequency difference in making distinction between
ECAs and EMAs (p = 0.245). The sensitivity of Method C
was 35.7%, indicating a high false negative rate, whereas,
the specificity of Method C is 81.0%, indicating a favora-
ble low false positive rate. Both the negative predictive
value (69.0%) and the positive predictive value (55.6%)
do not provide valuable information. However, the scor-
ing of p16INK4a expression using the other 2 mechanisms,
including Method N and Method Mean of C plus N,
shows significant frequency differences in making distinc-
tion between ECAs and EMAs (p < 0.05). The highest sen-
sitivity is 78.6% using Method N, the highest specificity is
85.7% using Method Mean of C plus N, the highest nega-
tive predictive value is 85% using Method N, whereas the
highest positive predictive value is 77.0% using Method
Mean of C plus N. Notably, Method Mean of C plus N has
the highest overall accuracy (80%).
In summary, of the three p16INK4a-scoring mechanisms,
Method N and Method Mean of C plus N are useful in dis-
tinguishing these two gynecologic adenocarcinomas (ECA
vs. EMA), whereas Method C is not. Using the Method
Mean of C plus N in p16INK4a-marker IHC assessments,
deserves the most favorable test effectiveness and per-
formance of all, which may not only assist physicians in
making adequate diagnostic distinction between ECAs
and EMAs, but also help individual patients by appropri-
ate treatment options. Despite the finite number of cases,
our data provides significant and valuable reference to
verify that p16INK4a with appropriate scoring mechanisms
can be applied in designing the appropriately diagnostic
multi-marker panels in distinguishing between ECAs and
EMAs.
Conclusion
Although careful gross and histologic examinations usu-
ally allows a confidant distinction between ECAs and
EMAs, diagnostic dilemma may occur when tumor is
localized in both endometrial and endocervical biopsies,
histomorphologic overlaps and preoperative imaging
studies may also confuse in establishing the site of origin.
True diagnosis may require the assistance of ancillary IHC
stains. The p16INK4a marker tends to be positively and dif-
fusely expressed in ECAs, but tends to be negatively or
focally expressed in EMAs. However, there is still a lack of
optimized consensus or standard for p16INK4a IHC scoring
mechanisms. According to the scientific results in this
study, we found that Method Mean of C plus N and
Method N can help to distinguish between ECAs and
EMAs, but Method C is of no use to do so. Based on the
data characteristics and test effectiveness, Method Mean of
C plus N is the most promising score-calculating means
among the three p16INK4a IHC scoring mechanisms in
diagnostic distinction between these two gynecologic
malignancies (ECAs vs. EMAs).
List of abbreviations used
ECAs: Endocervical adenocarcinomas; EMAs: Endome-
trial adenocarcinomas; p16: p16INK4a; IHC: Immunohis-
tochemistry, Method C: Independent cytoplasmic
staining alone; Method N: Independent nucleic staining
alone; Method Mean of C plus N: Mean of cytoplasmic
score plus nucleic score.
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